DAVITA INC. 10-K — AI Bull & Bear Analysis

The 2025 10-K reveals a company at a crossroads, balancing a successful operational pivot toward value-based care against a backdrop of high leverage and legal uncertainty. While the Integrated Kidney Care segment suggests a viable path to margin expansion, the financial risk remains elevated due to the scale of the company's debt obligations. Investors are left to weigh the benefits of a shrinking share count and improving operational efficiency against the possibility of adverse regulatory rulings. The company's ability to navigate 2026 Medicare rate adjustments and resolve federal inquiries will be critical in determining if the operational turnaround can outweigh the systemic financial risks.